Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
104.84
Nov 05 • 3:59 PM ET Dollar change-0.12 Percentage change(-0.11%)
Aftermarket Close
105.00
Aftermarket • 6:34 PM ET Dollar change+0.16 Percentage change(0.15%)
Nov 03, 2:40 PMMedtronic gets FDA approval for expanded U.S. label for Symplicity Spyral renal denervation system after positive SPYRAL AFFIRM real-world data
Index
S&P 500
Market Cap
134.11B
Enterprise Value
154.06B
Income
5.23B
Sales
37.54B
Book/sh
39.24
Cash/sh
6.89
Employees
95000
IPO
Nov 21, 1977
P/E
25.81
Forward P/E
16.39
PEG
2.12
P/S
3.57
P/B
2.67
P/C
15.21
P/FCF
21.87
EV/EBITDA
14.78
EV/Sales
4.10
Quick Ratio
1.54
Current Ratio
2.07
Debt/Eq
0.56
LT Debt/Eq
0.51
Option/Short
Yes / Yes
EPS (ttm)
4.06
EPS next Y
6.40
EPS next Q
1.33
EPS this Y
8.09%
EPS next Y
6.99%
EPS next 5Y
7.72%
EPS past 3/5Y
9.75% 6.95%
Sales past 3/5Y
5.21% 3.84%
EPS Y/Y TTM
12.28%
Sales Y/Y TTM
9.77%
EPS Q/Q
41.57%
Sales Q/Q
13.73%
Insider Own
0.09%
Insider Trans
-5.67%
Inst Own
88.88%
Inst Trans
-1.99%
ROA
5.68%
ROE
10.66%
ROIC
6.90%
Gross Margin
60.56%
Oper. Margin
19.93%
Profit Margin
13.93%
SMA20
9.47%
SMA50
13.37%
SMA200
18.83%
Trades
Shs Outstand
1.28B
Shs Float
1.28B
52W High
106.33 -1.40%
52W Low
73.31 43.01%
Volatility
2.88% 2.59%
ATR (14)
2.60
RSI (14)
73.30
Beta
0.57
Rel Volume
0.71
Avg Volume
16.38M
Volume
11,646,616
Perf Week
7.96%
Perf Month
22.61%
Perf Quarter
20.28%
Perf Half Y
34.48%
Perf YTD
9.14%
Perf Year
15.97%
Perf 3Y
44.49%
Perf 5Y
-14.75%
Perf 10Y
27.64%
Prev Close
104.96
Price
104.84
Change %
-0.11%
Consensus
Buy
Avg. Price Target
$103.82
Implied Upside
-1.0%
Analysts14incl. previous ratings
Rating Distribution8 Buy · 6 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 07, 2026Initiated
BCS logoBBarclays
Equal Weight$95-9.4%
Aug 27, 2026Reiterated
NNeedham
Buy$101 → $114+8.7%
Jul 28, 2026Upgrade
UBS logoUUBS
Neutral → Buy$100-4.6%
Jun 04, 2026Upgrade
BBTIG Research
Neutral → Buy$90-14.2%
May 21, 2026Resumed
GS logoGGoldman
Neutral$84-19.9%
Feb 13, 2026Resumed
BCS logoBBarclays
Overweight$116+10.6%
Feb 09, 2026Upgrade
NNeedham
Hold → Buy$121+15.4%
Feb 03, 2026Resumed
C logoCCitigroup
Buy$117+11.6%
Jan 30, 2026Resumed
WFC logoWWells Fargo
Overweight$114+8.7%
Jan 06, 2026Upgrade
WWilliam Blair
Mkt Perform → Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marinaro MichaelEVP, Pres MedSurg and AmericasOct 15 '26Sale96.0010,4201,000,320105,916Oct 16 06:02 PM
Martha GeoffreyChairman and CEOOct 15 '26Sale95.0050,0004,750,000277,866Oct 16 06:00 PM
Marinaro MichaelOfficerOct 15 '26Proposed Sale96.0010,4201,000,320Oct 15 05:00 PM
Martha GeoffreyOfficerOct 15 '26Proposed Sale95.0050,0004,750,000Oct 15 09:41 AM
KIIL HARRY SKIPEVP & President CardiovascularSep 16 '26Sale93.651,483138,88342,186Sep 17 04:17 PM
KIIL HARRY SKIPOfficerSep 16 '26Proposed Sale93.651,483138,889Sep 16 02:37 PM
Walter Matthew R.SVP, Chief HR OfficerJul 08 '26Sale83.153,102257,93135,694Jul 09 04:26 PM
Walter Matthew R.OfficerJul 08 '26Proposed Sale83.153,102257,931Jul 08 10:15 AM
KIIL HARRY SKIPEVP & President CardiovascularJun 08 '26Sale80.444,189336,96537,227Jun 09 04:16 PM
KIIL HARRY SKIPOfficerJun 08 '26Proposed Sale80.444,189336,965Jun 08 02:34 PM
Walter Matthew R.SVP, Chief HR OfficerMay 26 '26Option Exercise0.009,149041,529May 28 04:26 PM
Wall Brett A.EVP & Pres NeuroscienceMay 26 '26Option Exercise0.0026,907082,183May 28 04:26 PM
Martha GeoffreyChairman and CEOMay 26 '26Option Exercise0.0094,9630343,099May 28 04:25 PM
Marinaro MichaelEVP, Pres MedSurg and AmericasMay 26 '26Option Exercise0.0018,994070,593May 28 04:25 PM
KIIL HARRY SKIPEVP & President CardiovascularMay 26 '26Option Exercise0.0015,195048,233May 28 04:25 PM
Blomquist Denise L.Chief Accounting OfficerMay 26 '26Option Exercise0.001,712014,974May 28 04:24 PM
KIIL HARRY SKIPEVP & President CardiovascularFeb 19 '26Option Exercise90.9050,8764,624,51285,292Feb 26 05:48 PM
KIIL HARRY SKIPEVP & President CardiovascularFeb 19 '26Sale97.7152,5245,132,21732,768Feb 26 05:48 PM
KIIL HARRY SKIPOfficerFeb 19 '26Proposed Sale97.7152,5245,132,217Feb 19 03:19 PM
Smith Gregory LEVP Global Ops & Supply ChainNov 19 '25Sale101.9530,0003,058,45146,016Nov 21 04:13 PM
Smith Gregory LOfficerNov 19 '25Proposed Sale101.9530,0003,058,452Nov 19 11:05 AM
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Galway, Ireland.
Chairman of the Board & CEOMr. Geoffrey Straub Martha
SVP & Chief Operations and Supply Chain OfficerMr. Rogerio Branco
VPMs. Denise L. Blomquist
M.Sc.Dr. Laura Mauri M.D.
Vice President & Head of Investor RelationsMs. Ingrid Goldberg